MX2023001812A - Compuestos del acido azociclohexil acetico sustituidos por triazol-piridinilo como antagonistas del receptor lpa. - Google Patents

Compuestos del acido azociclohexil acetico sustituidos por triazol-piridinilo como antagonistas del receptor lpa.

Info

Publication number
MX2023001812A
MX2023001812A MX2023001812A MX2023001812A MX2023001812A MX 2023001812 A MX2023001812 A MX 2023001812A MX 2023001812 A MX2023001812 A MX 2023001812A MX 2023001812 A MX2023001812 A MX 2023001812A MX 2023001812 A MX2023001812 A MX 2023001812A
Authority
MX
Mexico
Prior art keywords
acetic acid
acid compounds
triazole
receptor antagonists
pyridinyl substituted
Prior art date
Application number
MX2023001812A
Other languages
English (en)
Inventor
Zhenwei Cai
Ping Chen
Hongjian Zhang
Fei Jiang
Peihua Sun
Original Assignee
Viva Star Biosciences Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Viva Star Biosciences Ltd filed Critical Viva Star Biosciences Ltd
Publication of MX2023001812A publication Critical patent/MX2023001812A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pulmonology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

La presente solicitud se refiere a nuevos compuestos de ácido acético de azociclohexilo sustituido, su fabricación, composiciones farmacéuticas que los comprenden, y su uso como medicamentos para tratar una enfermedad asociada con la desregulación de los receptores de ácido lisofosfatídico (LPA).
MX2023001812A 2020-08-11 2021-10-09 Compuestos del acido azociclohexil acetico sustituidos por triazol-piridinilo como antagonistas del receptor lpa. MX2023001812A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN2020108325 2020-08-11
PCT/IB2021/059266 WO2022034568A1 (en) 2020-08-11 2021-10-09 Triazole-pyridinyl substituted azacyclohexyl acetic acid compounds as lpa receptor antagonists

Publications (1)

Publication Number Publication Date
MX2023001812A true MX2023001812A (es) 2023-06-19

Family

ID=78179477

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2023001812A MX2023001812A (es) 2020-08-11 2021-10-09 Compuestos del acido azociclohexil acetico sustituidos por triazol-piridinilo como antagonistas del receptor lpa.

Country Status (9)

Country Link
EP (1) EP4196220A1 (es)
JP (1) JP2023544476A (es)
KR (1) KR20240068583A (es)
CN (1) CN116669727A (es)
AU (1) AU2021323515A1 (es)
CA (1) CA3191452A1 (es)
IL (1) IL300525A (es)
MX (1) MX2023001812A (es)
WO (1) WO2022034568A1 (es)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20220101137A (ko) 2019-11-15 2022-07-19 길리애드 사이언시즈, 인코포레이티드 Lpa 수용체 길항제로서의 트라이아졸 카르바메이트 피리딜 설폰아미드 및 이의 용도
AU2021282986B2 (en) 2020-06-03 2024-03-07 Gilead Sciences, Inc. LPA receptor antagonists and uses thereof
IL298082A (en) 2020-06-03 2023-01-01 Gilead Sciences Inc lpa receptor antagonists and uses thereof
KR20240044386A (ko) * 2021-04-30 2024-04-04 비바 스타 바이오사이언시즈 (쑤저우) 컴퍼니 리미티드 Lpa 길항제로서의 신규 트리아졸-피리딘 치환된 피롤리디닐 및 테트라히드로-2h-피라닐 아세트산 화합물
AU2022273631A1 (en) 2021-05-11 2023-11-02 Gilead Sciences, Inc. Lpa receptor antagonists and uses thereof
US11939318B2 (en) 2021-12-08 2024-03-26 Gilead Sciences, Inc. LPA receptor antagonists and uses thereof
TW202342017A (zh) 2022-02-25 2023-11-01 美商洛子峰生物有限公司 用於治療與ｌｐａ受體活性相關的病狀的化合物及組合物
CN117447450A (zh) * 2022-07-25 2024-01-26 武汉人福创新药物研发中心有限公司 三氮唑类化合物及其作为lpar1拮抗剂的用途

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK2443248T3 (en) * 2009-06-16 2018-03-12 Du Pont IMPROVEMENT OF LONG-CHAIN POLYUM Saturated OMEGA-3 AND OMEGA-6 FATTY ACID BIOS SYNTHESIS BY EXPRESSION OF ACYL-CoA LYSOPHOSPHOLIPID ACYL TRANSFERASES
WO2012100436A1 (en) * 2011-01-30 2012-08-02 Curegenix Inc. Compound as antagonist of lysophosphatidic acid receptor, composition, and use thereof
WO2012138648A1 (en) * 2011-04-06 2012-10-11 Irm Llc Compositions and methods for modulating lpa receptors
US9663513B2 (en) 2012-11-20 2017-05-30 Merck Sharp & Dohme Corp. Pyrimidine PDE10 inhibitors
US20140200215A1 (en) * 2013-01-15 2014-07-17 Intermune, Inc. Lysophosphatidic acid receptor antagonists
JP6482086B2 (ja) * 2013-03-15 2019-03-13 エピゲン バイオサイエンシズ, インコーポレイテッドEpigen Biosciences, Inc. 疾患の治療に有用な複素環化合物
US11261180B2 (en) * 2017-12-19 2022-03-01 Bristol-Myers Squibb Company Cyclohexyl acid isoxazole azoles as LPA antagonists
JP7202383B2 (ja) * 2017-12-19 2023-01-11 ブリストル－マイヤーズ スクイブ カンパニー Ｌｐａアンタゴニストとしてのピラゾールｏ－架橋カルバモイルシクロヘキシル酸

Also Published As

Publication number Publication date
WO2022034568A1 (en) 2022-02-17
IL300525A (en) 2023-04-01
AU2021323515A1 (en) 2023-03-09
EP4196220A1 (en) 2023-06-21
KR20240068583A (ko) 2024-05-17
CA3191452A1 (en) 2022-02-17
JP2023544476A (ja) 2023-10-24
CN116669727A (zh) 2023-08-29

Similar Documents

Publication Publication Date Title
MX2023001812A (es) Compuestos del acido azociclohexil acetico sustituidos por triazol-piridinilo como antagonistas del receptor lpa.
JOP20210017A1 (ar) مثبطات جسيم التهابي nlrp3
TN2018000043A1 (en) Novel 6-6 bicyclic aromatic ring substituted nucleoside analogues for use as prmt5 inhibitors
CR10875A (es) Derivados de ester y amida de indazolilo para el tratamiento de enfermedades mediadas por un receptor de glucocorticoides
CY1116328T1 (el) Παραγωγα 4 - αμινοπυριμιδινης και η χρηση τους ως ανταγωνιστων α2α υποδοχεων αδενοσινης
UY35572A (es) Nuevos agonistas del receptor de somatostatina subtipo 4 (sstr4)
SV2010003580A (es) Agonistas novedosos de los receptores de glucocorticoides
EA200970967A1 (ru) Оксадиазол замещенные производные индазола для применения в качестве агонистов сфингозин 1-фосфата (sip)
CL2007003826A1 (es) Compuestos derivados de n-(amino-(hetero)aril)-1h-pirrolopiridin-2-carboxamidas, antagonistas de receptores tipo trpv1; procedimiento de preparacion; composicion farmaceutica; y uso para el tratamiento de enfermedades tales como trastornos gastrointestinales, trastornos respiratorios, psoriasis y depresion.
PE20090890A1 (es) Compuestos derivados de 1-(2,3-dihidrobenzo[1,4]dioxin-2-ilmetil)azaciclos como antagonistas del suptipo adrenoreceptor alfa2c
AR111570A1 (es) Composición farmacéutica que comprende selexipag
MX2013008431A (es) Antagonista del receptor de mineralocorticoides.
BR112012023178A2 (pt) ramidinas substituídas como antagonistas de receptor prostaglandina 2
EA202091256A1 (ru) Новые антагонисты рецептора брадикинина
JO2937B1 (en) Tight muscles of the peptide vascular tensioner receptor
CY1113759T1 (el) Ταχεως διασπομενοι ανταγωνιστες υποδοχεα ντοπαμινης 2
PE20181319A1 (es) Compuestos de isoindol
PE20160284A1 (es) Derivados de amida como antogonistas del receptor de acido lisofosfatidico
MX345544B (es) Derivados de triazol como ligandos para receptores de acido gamma-aminobutirico (gaba).
ZA202109193B (en) A substituted tetrahydroisoquinoline derivative as a d1 positive allosteric modulator
MX2011013869A (es) Agentes antihelminticos y su uso.
ECSP10010606A (es) Derivados de quinuclidina como antagonistas de receptores muscarinicos m3
MX2013008531A (es) Nuevos compuestos de benzodioxol-piperazina.
AR071721A1 (es) Derivados de piridil-prolinamida, composiciones farmaceuticas que los contienen y su uso para el tratamiento de ansiedad, depresion y trastornos del sueno.
CO6351775A2 (es) Forma cristalina de un acido alcoxiimidazol-1-ilmetil bifenil carboxilico